| Primary |
| Idiopathic Thrombocytopenic Purpura |
11.4% |
| Guillain-barre Syndrome |
7.9% |
| Immunodeficiency Common Variable |
7.9% |
| Product Used For Unknown Indication |
7.9% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
7.0% |
| Immunisation |
7.0% |
| Drug Use For Unknown Indication |
6.1% |
| Histiocytosis Haematophagic |
6.1% |
| Bruton's Agammaglobulinaemia |
4.4% |
| Haematology Test Abnormal |
4.4% |
| Lichen Myxoedematosus |
4.4% |
| Polymyositis |
4.4% |
| Human Herpesvirus 6 Infection |
3.5% |
| Myasthenia Gravis |
3.5% |
| Primary Immunodeficiency Syndrome |
3.5% |
| Antiemetic Supportive Care |
2.6% |
| Sepsis |
2.6% |
| Bone Marrow Failure |
1.8% |
| Hypogammaglobulinaemia |
1.8% |
| Immunodeficiency |
1.8% |
|
| Urticaria |
11.1% |
| Renal Failure Acute |
9.3% |
| Haemolytic Anaemia |
7.4% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
7.4% |
| Tachypnoea |
5.6% |
| Tremor |
5.6% |
| Vomiting |
5.6% |
| Cerebrovascular Accident |
3.7% |
| Haemorrhage |
3.7% |
| Hypersensitivity |
3.7% |
| Infusion Related Reaction |
3.7% |
| Oxygen Saturation Decreased |
3.7% |
| Pancytopenia |
3.7% |
| Serum Sickness |
3.7% |
| Tachycardia |
3.7% |
| Thrombophlebitis |
3.7% |
| Transplant Rejection |
3.7% |
| Urinary Incontinence |
3.7% |
| Vasculitis |
3.7% |
| Wheezing |
3.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
29.0% |
| Pregnancy |
26.3% |
| Product Used For Unknown Indication |
8.4% |
| Idiopathic Thrombocytopenic Purpura |
5.1% |
| Haematology Test Abnormal |
4.6% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Gastrooesophageal Reflux Prophylaxis |
3.4% |
| Antiemetic Supportive Care |
2.9% |
| Lung Transplant |
2.4% |
| Febrile Neutropenia |
2.3% |
| Prophylaxis Against Graft Versus Host Disease |
2.0% |
| Infection Prophylaxis |
1.3% |
| Rheumatoid Arthritis |
1.3% |
| Autoimmune Thrombocytopenia |
1.2% |
| Histiocytosis Haematophagic |
1.1% |
| Multiple Sclerosis |
1.1% |
| Bacteraemia |
1.0% |
| Immunosuppression |
1.0% |
| Immunisation |
0.9% |
| Myelodysplastic Syndrome |
0.9% |
|
| Neurotoxicity |
54.0% |
| Drug Exposure During Pregnancy |
9.5% |
| Metal Poisoning |
8.5% |
| Adverse Event |
4.9% |
| Vomiting |
2.6% |
| Pharmaceutical Product Complaint |
2.2% |
| Viral Pharyngitis |
2.0% |
| Neurological Symptom |
1.8% |
| Renal Failure Acute |
1.6% |
| Vacuum Extractor Delivery |
1.6% |
| Myopathy |
1.4% |
| Nervous System Disorder |
1.4% |
| Speech Disorder Developmental |
1.4% |
| Pyrexia |
1.2% |
| Rash Maculo-papular |
1.2% |
| Haemoglobin Decreased |
1.0% |
| Hypofibrinogenaemia |
1.0% |
| Rectal Haemorrhage |
1.0% |
| Transplant Rejection |
1.0% |
| Vaginal Haemorrhage |
1.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
18.2% |
| Prophylaxis |
16.8% |
| Idiopathic Thrombocytopenic Purpura |
6.4% |
| Systemic Lupus Erythematosus |
5.7% |
| Infection Prophylaxis |
5.6% |
| Premedication |
5.4% |
| Psoriatic Arthropathy |
5.3% |
| Prophylaxis Against Graft Versus Host Disease |
5.2% |
| Bone Marrow Conditioning Regimen |
4.0% |
| Constipation |
3.9% |
| Drug Use For Unknown Indication |
3.0% |
| Osteoporosis |
2.9% |
| Antibiotic Prophylaxis |
2.5% |
| Pyrexia |
2.5% |
| Antifungal Prophylaxis |
2.3% |
| Prophylaxis Of Nausea And Vomiting |
2.3% |
| Pneumocystis Jiroveci Pneumonia |
2.1% |
| Multiple Myeloma |
2.0% |
| Antiviral Prophylaxis |
1.9% |
| Insomnia |
1.9% |
|
| Wound Infection Staphylococcal |
12.2% |
| Drug Ineffective |
8.9% |
| Thrombocytopenia |
7.8% |
| Vomiting |
6.7% |
| Wound Secretion |
6.7% |
| Haemorrhage |
5.6% |
| Septic Shock |
5.6% |
| Ventricular Extrasystoles |
5.6% |
| Transaminases Increased |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Acute Graft Versus Host Disease In Skin |
3.3% |
| Histiocytosis Haematophagic |
3.3% |
| Infection |
3.3% |
| Inflammation |
3.3% |
| Rash Maculo-papular |
3.3% |
| Respiratory Failure |
3.3% |
| Sepsis |
3.3% |
| Skin Exfoliation |
3.3% |
| Tinea Versicolour |
3.3% |
| Acute Respiratory Distress Syndrome |
2.2% |
|
